Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b9036c33bbe3f4ea428655b76200f7c |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-198 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522 |
filingDate |
2003-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad47fda10e506b9b90bb8337dea6a757 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_068fe7273b66baa9df10cd17b15edab4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92579ff8eb90242460cd544a6084a6b9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_686f112a2809955b93710f85c94c9e13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c297d3e223a1bac8f96fa7b3ad1e35fd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ad52fb4db77e3198fd2fd4bed8003e3 |
publicationDate |
2015-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-2942082-A2 |
titleOfInvention |
A2A receptor antogonists for use in the treatment of movement disorders |
abstract |
The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A 2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A 2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A 2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A 2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication. |
priorityDate |
2002-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |